针对内质网膜压力的策略,以改善帕金森病的病情
Danni Wang1, Shuhui Qu1, Zaijun Zhang2
1State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, China.
Frontiers in pharmacology
|November 29, 2023
概括
细胞内膜网膜 (ER) 的压力通过引起多巴胺能神经元死亡,导致帕金森病 (PD). 针对ER压力路径为PD治疗提供了一个有前途的治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 细胞生物学 细胞生物学
- 病理学 病理学 病理学
背景情况:
- 帕金森病 (PD) 涉及黑色物质中多巴胺基 (DA) 神经元的逐渐死亡.
- 在SNPc DA神经元中的内质网膜 (ER) 应激是PD病变发生的早期事件.
- ER压力激活了未折叠的蛋白质反应 (UPR),如果长时间延长,可能会加剧DA神经元死亡.
研究的目的:
- 审查ER压力在帕金森病中的病理作用.
- 更新针对ER应激治疗PD治疗的战略.
主要方法:
- 对ER压力和帕金森病研究的文献综述.
- 对针对ER压力路径的治疗策略的分析.
主要成果:
- ER压力是PD中多巴胺基神经元损失的重要贡献者.
- 调节UPR信号,增强蛋白质折叠和改善蛋白质降解是关键的治疗方法.
- 这些策略旨在恢复ER蛋白的平衡,并减轻PD相关事件.
结论:
- 紧急救护室的压力是帕金森病的关键治疗目标.
- 开发管理ER压力和UPR的干预措施对于减轻PD神经元死亡至关重要.
相关概念视频
Parkinson's Disease: Treatment
276
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
276
Parkinson's Disease: Overview
557
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
557
EPS and iPS Cells in Disease Research
2.8K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
2.8K
Neural Regulation
39.5K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.5K
Lysosomal Hydrolases
3.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K
Alzheimer's Disease: Treatment
195
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195


